🇺🇸·4h agoIndustry
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Publisher
M
Merck & Co. (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck & Co. (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- June 18, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/4h ago
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Ipsen RSS/6h ago
Advancing Care in Renal Cell Carcinoma: Earlier Treatment, Better Outcomes, and Stronger Support for Patients
Roche Newsroom/10h ago
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Natco Pharma/15h ago